<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>650</number>
    <updateDate>2023-01-15T23:03:28Z</updateDate>
    <updateDateIncludingText>2023-01-15T23:03:28Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <originChamberCode>S</originChamberCode>
    <type>S</type>
    <introducedDate>2003-03-18</introducedDate>
    <congress>108</congress>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
            <activities>
              <item>
                <name>Referred to</name>
                <date>2003-08-08T14:45:10Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2003-07-25T00:40:26Z</date>
          </item>
        </activities>
      </item>
      <item>
        <systemCode>sshr00</systemCode>
        <name>Health, Education, Labor, and Pensions Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Reported by</name>
            <date>2003-06-27T05:50:57Z</date>
          </item>
          <item>
            <name>Markup by</name>
            <date>2003-03-19T21:55:21Z</date>
          </item>
          <item>
            <name>Referred to</name>
            <date>2003-03-19T01:34:02Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <committeeReports>
      <committeeReport>
        <citation>S. Rept. 108-84</citation>
      </committeeReport>
    </committeeReports>
    <relatedBills>
      <item>
        <title>Pediatric Research Equity Act of 2003</title>
        <congress>108</congress>
        <number>2857</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2003-08-08</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2003-12-03</actionDate>
        <text>Became Public Law No: 108-155.</text>
        <type>President</type>
        <actionCode>E40000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-12-03</actionDate>
        <text>Became Public Law No: 108-155.</text>
        <type>BecameLaw</type>
        <actionCode>36000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-12-03</actionDate>
        <text>Signed by President.</text>
        <type>President</type>
        <actionCode>E30000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-12-03</actionDate>
        <text>Signed by President.</text>
        <type>BecameLaw</type>
        <actionCode>36000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-11-21</actionDate>
        <text>Presented to President.</text>
        <type>Floor</type>
        <actionCode>E20000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-11-21</actionDate>
        <text>Presented to President.</text>
        <type>President</type>
        <actionCode>28000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-11-19</actionDate>
        <actionTime>15:55:22</actionTime>
        <text>Motion to reconsider laid on the table Agreed to without objection.</text>
        <type>Floor</type>
        <actionCode>H38310</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-11-19</actionDate>
        <actionTime>15:55:05</actionTime>
        <text>On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H11567-11569)</text>
        <type>Floor</type>
        <actionCode>H37300</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-11-19</actionDate>
        <actionTime>15:55:05</actionTime>
        <text>Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H11567-11569)</text>
        <type>Floor</type>
        <actionCode>8000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-11-19</actionDate>
        <actionTime>15:27:31</actionTime>
        <text>DEBATE - The House proceeded with forty minutes of debate on S. 650.</text>
        <type>Floor</type>
        <actionCode>H8D000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-11-19</actionDate>
        <actionTime>15:27:29</actionTime>
        <text>Considered under suspension of the rules. (consideration: CR H11567-11572)</text>
        <type>Floor</type>
        <actionCode>H30000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-11-19</actionDate>
        <actionTime>15:27:12</actionTime>
        <text>Mr. Bilirakis moved to suspend the rules and pass the bill.</text>
        <type>Floor</type>
        <actionCode>H30300</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-08-08</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2003-07-24</actionDate>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2003-07-24</actionDate>
        <actionTime>10:04:19</actionTime>
        <text>Received in the House.</text>
        <type>Floor</type>
        <actionCode>H14000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-07-24</actionDate>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Message on Senate action sent to the House.</text>
        <type>Floor</type>
      </item>
      <item>
        <actionDate>2003-07-23</actionDate>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Passed Senate with amendments by Unanimous Consent. (text as passed Senate: CR S9816-9818)</text>
        <type>Floor</type>
      </item>
      <item>
        <actionDate>2003-07-23</actionDate>
        <text>Passed/agreed to in Senate: Passed Senate with amendments by Unanimous Consent.(text as passed Senate: CR S9816-9818)</text>
        <type>Floor</type>
        <actionCode>17000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-07-23</actionDate>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Measure laid before Senate by unanimous consent. (consideration:  CR S9811-9819; text of measure as reported in Senate:  CR S9811-9813)</text>
        <type>Floor</type>
      </item>
      <item>
        <actionDate>2003-06-27</actionDate>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 183.</text>
        <type>Calendars</type>
      </item>
      <item>
        <actionDate>2003-06-27</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Committee on Health, Education, Labor, and Pensions. Reported by Senator Gregg with an amendment. With written report No. 108-84. Additional views filed.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2003-06-27</actionDate>
        <text>Committee on Health, Education, Labor, and Pensions. Reported by Senator Gregg with an amendment. With written report No. 108-84. Additional views filed.</text>
        <type>Committee</type>
        <actionCode>14000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2003-03-19</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment favorably.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2003-03-18</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S3898-3900)</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2003-03-18</actionDate>
        <text>Sponsor introductory remarks on measure. (CR S3897-3898)</text>
        <type>IntroReferral</type>
        <actionCode>B00100</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-03-18</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>D000294</bioguideId>
        <fullName>Sen. DeWine, Mike [R-OH]</fullName>
        <firstName>MICHAEL</firstName>
        <lastName>DEWINE</lastName>
        <party>R</party>
        <state>OH</state>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>C001041</bioguideId>
        <fullName>Sen. Clinton, Hillary Rodham [D-NY]</fullName>
        <firstName>HILLARY</firstName>
        <lastName>CLINTON</lastName>
        <party>D</party>
        <state>NY</state>
        <middleName>R</middleName>
        <sponsorshipDate>2003-03-18</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>G000445</bioguideId>
        <fullName>Sen. Gregg, Judd [R-NH]</fullName>
        <firstName>Judd</firstName>
        <lastName>Gregg</lastName>
        <party>R</party>
        <state>NH</state>
        <sponsorshipDate>2003-03-18</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>D000388</bioguideId>
        <fullName>Sen. Dodd, Christopher J. [D-CT]</fullName>
        <firstName>CHRISTOPHER</firstName>
        <lastName>DODD</lastName>
        <party>D</party>
        <state>CT</state>
        <middleName>JOHN</middleName>
        <sponsorshipDate>2003-03-18</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>K000105</bioguideId>
        <fullName>Sen. Kennedy, Edward M. [D-MA]</fullName>
        <firstName>EDWARD</firstName>
        <lastName>KENNEDY</lastName>
        <party>D</party>
        <state>MA</state>
        <middleName>MOORE</middleName>
        <sponsorshipDate>2003-03-18</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>M001111</bioguideId>
        <fullName>Sen. Murray, Patty [D-WA]</fullName>
        <firstName>Patty</firstName>
        <lastName>Murray</lastName>
        <party>D</party>
        <state>WA</state>
        <sponsorshipDate>2003-03-19</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>F000439</bioguideId>
        <fullName>Sen. Frist, William H. [R-TN]</fullName>
        <firstName>WILLIAM</firstName>
        <lastName>FRIST</lastName>
        <party>R</party>
        <state>TN</state>
        <middleName>H.</middleName>
        <sponsorshipDate>2003-03-19</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <cboCostEstimates>
      <item>
        <pubDate>2003-07-15T04:00:00Z</pubDate>
        <title>S. 650, Pediatric Research Equity Act of 2003</title>
        <url>http://www.cbo.gov/publication/14632</url>
        <description>&lt;p&gt;Cost estimate for the bill as reported by the Senate Committee on Health, Education, Labor, and Pensions on June 27, 2003&lt;/p&gt;</description>
      </item>
      <item>
        <pubDate>2003-07-15T04:00:00Z</pubDate>
        <title>S. 650, Pediatric Research Equity Act of 2003</title>
        <url>https://www.cbo.gov/publication/14632</url>
        <description>Cost estimate for the bill as reported by the Senate Committee on Health, Education, Labor, and Pensions on June 27, 2003</description>
      </item>
    </cboCostEstimates>
    <laws>
      <item>
        <type>Public Law</type>
        <number>108-155</number>
      </item>
    </laws>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Administrative remedies</name>
        </item>
        <item>
          <name>Child health</name>
        </item>
        <item>
          <name>Child safety</name>
        </item>
        <item>
          <name>Clinical trials</name>
        </item>
        <item>
          <name>Commerce</name>
        </item>
        <item>
          <name>Department of Health and Human Services</name>
        </item>
        <item>
          <name>Drug approvals</name>
        </item>
        <item>
          <name>Drug industry</name>
        </item>
        <item>
          <name>Drugs</name>
        </item>
        <item>
          <name>Families</name>
        </item>
        <item>
          <name>Government Operations and Politics</name>
        </item>
        <item>
          <name>Government paperwork</name>
        </item>
        <item>
          <name>Labeling</name>
        </item>
        <item>
          <name>Law</name>
        </item>
        <item>
          <name>Licenses</name>
        </item>
        <item>
          <name>Pharmaceutical research</name>
        </item>
        <item>
          <name>Product safety</name>
        </item>
        <item>
          <name>Science, Technology, Communications</name>
        </item>
        <item>
          <name>Warning labels</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2003-03-18</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2006-11-28T17:35:40Z</updateDate>
        <text><![CDATA[Pediatric Research Equity Act of 2003 - Amends the Federal Food, Drug, and Cosmetic Act to require license applications for new drugs and biological products to assess such drug's or product's safety and effectiveness for relevant pediatric subpopulations, including dosage.<p>Permits deferral of such assessments under specified circumstances.<p>Permits full waiver of such assessments under certain conditions, including if: (1) studies are highly impractical or impossible; or (2) there is no meaningful therapeutic advantage or benefit in the pediatric population.<p>Permits partial waivers at the request of an applicant for a specific pediatric subpopulation if any of the full waiver grounds apply to that subpopulation or reasonable attempts for a pediatric formulation for that subpopulation have failed.<p>Requires labels to provide indication in cases in which a waiver has been granted due to evidence a product would be unsafe or ineffective in pediatric populations.<p>Authorizes the Secretary of Health and Human Services to specify a date for submission of pediatric assessments if: (1) the drug or biological product would represent a meaningful therapeutic benefit for pediatric patients for one or more claimed indications and the absence of adequate labeling could pose significant risks to pediatric patients; or (2) it is used for a number of pediatric patients for the labeled indications and the absence of adequate labeling could pose significant risks to pediatric patients. Sets forth criteria for full waiver and partial waivers of such requirement. Requires labels to provide indication in cases in which a waiver has been granted due to evidence a product would be unsafe or ineffective in pediatric populations.<p>Requires the Secretary to issue a written request for related pediatric studies under the Public Health Service Act or under this Act before requiring an assessment for a drug. Directs the Secretary, after determining that there is no agreement to such a written request, to certify whether the Secretary has sufficient funds to conduct the study under the Public Health Service Act, taking into account prioritization of drugs for which pediatric studies are needed.<p>States that if a person fails to submit an assessment under this Act, or a request for approval of a pediatric formulation, the relevant drug or biological product may be considered misbranded and subject to enforcement action.]]></text>
      </summary>
      <summary>
        <versionCode>35</versionCode>
        <actionDate>2003-07-23</actionDate>
        <actionDesc>Passed Senate amended</actionDesc>
        <updateDate>2007-05-09T21:37:15Z</updateDate>
        <text><![CDATA[ <p>Pediatric Research Equity Act of 2003 - Amends the Federal Food, Drug, and Cosmetic Act to require license applications for new drugs and biological products to assess such drug's or product's safety and effectiveness for relevant pediatric subpopulations, including dosage. </p> <p>Permits deferral of such assessments under specified circumstances, including if the Secretary of Health and Human Services finds that the drug or biological product is ready for approval for use in adults before pediatric studies are complete. <p>Permits full waiver of such assessments under certain conditions, including if: (1) studies are highly impractical or impossible; or (2) there is no meaningful therapeutic advantage or benefit in the pediatric population and the drug or biological product is not likely to be used in a substantial number of pediatric patients. <p>Permits partial waivers at the request of an applicant for a specific pediatric subpopulation if any of the full waiver grounds apply to that subpopulation or reasonable attempts for a pediatric formulation for that subpopulation have failed.<p>Requires labels to provide indication in cases in which a waiver has been granted due to evidence a product would be unsafe or ineffective in pediatric populations. <p>Authorizes the Secretary of Health and Human Services to specify a date for submission of pediatric assessments if: (1) the drug or biological product would represent a meaningful therapeutic benefit for pediatric patients for one or more claimed indications and the absence of adequate labeling could pose significant risks to pediatric patients; or (2) it is used for a substantial number of pediatric patients for the labeled indications and the absence of adequate labeling could pose significant risks to pediatric patients. Sets forth criteria for full waiver and partial waivers of such requirement. Requires labels to provide indication in cases in which a waiver has been granted due to evidence a product would be unsafe or ineffective in pediatric populations. <p>Requires the Secretary to issue a written request for related pediatric studies under the Public Health Service Act or under this Act before requiring an assessment for a drug. Directs the Secretary, after determining that there is no agreement to such a written request, to certify whether the Secretary has sufficient funds to conduct the study under the Public Health Service Act, taking into account prioritization of drugs for which pediatric studies are needed. <p>States that if a person fails to submit an assessment under this Act, or a request for approval of a pediatric formulation, the relevant drug or biological product may be considered misbranded solely because of that failure and subject to relevant enforcement action. <p>Provides that the new authority under this Act to require pediatric studies shall only remain in effect so long as the pediatric exclusivity provisions under the Federal Food, Drug, and Cosmetic Act also remain in effect (until October 1, 2007). <p>(Sec. 4) Declares that the provisions of this Act pertaining to research into pediatric uses for new drugs and biological products shall apply to license applications for such drugs and products submitted to the Secretary on or after April 1, 1999. Specifies procedures for the treatment of applications submitted between April 1, 1999, and the date of the enactment of this Act with respect to which waivers or deferrals were granted under previous regulations and with respect to which no waivers or deferrals were granted.]]></text>
      </summary>
      <summary>
        <versionCode>49</versionCode>
        <actionDate>2003-12-03</actionDate>
        <actionDesc>Public Law</actionDesc>
        <updateDate>2004-01-16T19:57:39Z</updateDate>
        <text><![CDATA[ <p><b>(This measure has not been amended since it was passed by the Senate on July 23, 2003. The summary of that version is repeated here.)</b></p> <p>Pediatric Research Equity Act of 2003 - (Sec. 2) Amends the Federal Food, Drug, and Cosmetic Act to require license applications for new drugs and biological products to assess such drug's or product's safety and effectiveness for relevant pediatric subpopulations, including dosage.</p> <p>Permits deferral of such assessments under specified circumstances, including if the Secretary of Health and Human Services finds that the drug or biological product is ready for approval for use in adults before pediatric studies are complete. <p>Permits full waiver of such assessments under certain conditions, including if: (1) studies are highly impractical or impossible; or (2) there is no meaningful therapeutic advantage or benefit in the pediatric population and the drug or biological product is not likely to be used in a substantial number of pediatric patients. <p>Permits partial waivers at the request of an applicant for a specific pediatric subpopulation if any of the full waiver grounds apply to that subpopulation or reasonable attempts for a pediatric formulation for that subpopulation have failed.<p>Requires labels to provide indication in cases in which a waiver has been granted due to evidence a product would be unsafe or ineffective in pediatric populations. <p>Authorizes the Secretary to specify a date for submission of pediatric assessments if: (1) the drug or biological product would represent a meaningful therapeutic benefit for pediatric patients for one or more claimed indications and the absence of adequate labeling could pose significant risks to pediatric patients; or (2) it is used for a substantial number of pediatric patients for the labeled indications and the absence of adequate labeling could pose significant risks to pediatric patients. Sets forth criteria for full waiver and partial waivers of such requirement. Requires labels to provide indication in cases in which a waiver has been granted due to evidence a product would be unsafe or ineffective in pediatric populations. <p>Requires the Secretary to issue a written request for related pediatric studies under the Public Health Service Act or under this Act before requiring an assessment for a drug. Directs the Secretary, after determining that there is no agreement to such a written request, to certify whether the Secretary has sufficient funds to conduct the study under the Public Health Service Act, taking into account prioritization of drugs for which pediatric studies are needed. <p>States that if a person fails to submit an assessment under this Act, or a request for approval of a pediatric formulation, the relevant drug or biological product may be considered misbranded solely because of that failure and subject to relevant enforcement action. <p>Provides that the new authority under this Act to require pediatric studies shall only remain in effect so long as the pediatric exclusivity provisions under the Federal Food, Drug, and Cosmetic Act also remain in effect (until October 1, 2007). <p>(Sec. 4) Declares that the provisions of this Act pertaining to research into pediatric uses for new drugs and biological products shall apply to license applications for such drugs and products submitted to the Secretary on or after April 1, 1999. Specifies procedures for the treatment of applications submitted between April 1, 1999, and the date of the enactment of this Act with respect to which waivers or deferrals were granted under previous regulations and with respect to which no waivers or deferrals were granted.]]></text>
      </summary>
    </summaries>
    <title>Pediatric Research Equity Act of 2003</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Pediatric Research Equity Act of 2003</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to amend the Federal Food, Drug, and Cosmetic Act to authorize the Food and Drug Administration to require certain research into drugs used in pediatric patients.</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>Pediatric Research Equity Act of 2003</title>
      </item>
      <item>
        <titleType>Short Titles as Passed Senate</titleType>
        <title>Pediatric Research Equity Act of 2003</title>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
      </item>
      <item>
        <titleType>Short Titles as Enacted</titleType>
        <title>Pediatric Research Equity Act of 2003</title>
      </item>
    </titles>
    <amendments>
      <amendment>
        <number>1360</number>
        <congress>108</congress>
        <type>SAMDT</type>
        <purpose>Relative to the applicability to new drugs and biological products.</purpose>
        <updateDate>2022-02-25T17:33:46Z</updateDate>
        <latestAction>
          <actionDate>2003-07-23</actionDate>
          <text>Amendment SA 1360 agreed to in Senate by Unanimous Consent.</text>
          <links>
            <link>
              <name>SA 1360</name>
              <url>https://www.congress.gov/amendment/108th-congress/senate-amendment/1360</url>
            </link>
          </links>
        </latestAction>
        <sponsors>
          <item>
            <bioguideId>G000445</bioguideId>
            <fullName>Sen. Gregg, Judd [R-NH]</fullName>
            <firstName>Judd</firstName>
            <lastName>Gregg</lastName>
            <party>R</party>
            <state>NH</state>
          </item>
        </sponsors>
        <proposedDate>2003-07-23T04:00:00Z</proposedDate>
        <submittedDate>2003-07-23T04:00:00Z</submittedDate>
        <chamber>Senate</chamber>
        <amendedBill>
          <congress>108</congress>
          <type>S</type>
          <originChamber>Senate</originChamber>
          <originChamberCode>S</originChamberCode>
          <number>650</number>
          <title>Pediatric Research Equity Act of 2003</title>
          <updateDateIncludingText>2023-01-15T23:03:28Z</updateDateIncludingText>
        </amendedBill>
        <actions>
          <count>6</count>
          <actions>
            <item>
              <actionDate>2003-07-23</actionDate>
              <sourceSystem>
                <code>0</code>
                <name>Senate</name>
              </sourceSystem>
              <text>Amendment SA 1360 agreed to in Senate by Unanimous Consent.</text>
              <type>Floor</type>
            </item>
            <item>
              <actionDate>2003-07-23</actionDate>
              <sourceSystem>
                <code>0</code>
                <name>Senate</name>
              </sourceSystem>
              <text>Amendment SA 1360 proposed by Senator DeWine for Senator Gregg. (consideration:  CR S9815-9816; text:  CR S9815) Relative to the applicability to new drugs and biological products.</text>
              <type>Floor</type>
            </item>
            <item>
              <actionDate>2003-07-23</actionDate>
              <text>Senate amendment proposed (on the floor): Amendment SA 1360 proposed by Senator DeWine for Senator Gregg.(consideration:  CR S9815-9816; text:  CR S9815)</text>
              <type>Floor</type>
              <actionCode>93000</actionCode>
              <sourceSystem>
                <code>9</code>
                <name>Library of Congress</name>
              </sourceSystem>
            </item>
            <item>
              <actionDate>2003-07-23</actionDate>
              <text>Senate amendment agreed to: Amendment SA 1360 agreed to in Senate by Unanimous Consent.</text>
              <type>Floor</type>
              <actionCode>94000</actionCode>
              <sourceSystem>
                <code>9</code>
                <name>Library of Congress</name>
              </sourceSystem>
            </item>
            <item>
              <actionDate>2003-07-23</actionDate>
              <text>Senate amendment submitted</text>
              <type>Floor</type>
              <actionCode>91000</actionCode>
              <sourceSystem>
                <code>9</code>
                <name>Library of Congress</name>
              </sourceSystem>
            </item>
          </actions>
        </actions>
      </amendment>
    </amendments>
    <textVersions>
      <item>
        <type>Enrolled Bill</type>
        <date/>
        <formats/>
      </item>
      <item>
        <type>Referred in House</type>
        <date>2003-07-24T04:00:00Z</date>
        <formats/>
      </item>
      <item>
        <type>Engrossed in Senate</type>
        <date>2003-07-23T04:00:00Z</date>
        <formats/>
      </item>
      <item>
        <type>Reported to Senate</type>
        <date>2003-06-27T04:00:00Z</date>
        <formats/>
      </item>
      <item>
        <type>Introduced in Senate</type>
        <date>2003-03-18T05:00:00Z</date>
        <formats/>
      </item>
      <item>
        <date>2003-12-04T04:59:59Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/PLAW-108publ155/xml/PLAW-108publ155.xml</url>
          </item>
        </formats>
        <type>Public Law</type>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2003-12-03</actionDate>
      <text>Became Public Law No: 108-155.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
